EXTRACELLULAR MATRIX MARKET ANALYSIS

The extracellular matrix market size is expected to reach US$ 64.1 Mn by 2030, from US$ 37.9 Mn in 2023, at a CAGR of 7.8% during the forecast period. Extracellular matrix (ECM) provides structural and biochemical support to surrounding cells. ECM has applications in cell culture, engineering, and clinical use. The key drivers are rising demand for cell culture research and tissue regeneration.

Extracellular Matrix Market Regional Insights

• North America is expected to be the largest market for the extracellular matrix market during the forecast period, accounting for over 40.5% of the market share in 2023. The growth of the market in North America is attributed to the high investments in research and development, and advanced healthcare infrastructure. 
• The Europe market is expected to be the second-largest market for the extracellular matrix market, accounting for over 28.7% of the market share in 2023. The growth of the market in Europe is attributed to the rising prevalence of chronic wounds.
• The Asia Pacific market is expected to be the fastest-growing market for the extracellular matrix market, with a CAGR of over 10.2% during the forecast period. The growth of the market in Asia Pacific is attributed to the expanding biotechnology sector and increasing demand for regenerative medicines.

Figure 1. Extracellular Matrix Market Share (%), by Region, 2023

To learn more about this report, request a free sample copy

Analyst View

• The global extracellular matrix market is poised to grow steadily over the next few years. The increasing prevalence of chronic wounds and musculoskeletal disorders are the major drivers boosting adoption of extracellular matrix products. Further, the rising geriatric population worldwide susceptible to such conditions will further propel demand. However, high costs of these therapies may hamper market growth to some extent.
• North America dominates currently and is expected to continue its leadership during the forecast period. Higher awareness about advanced wound care therapies and a large base of orthopedic and sports medicine companies in the US are influencing the region's substantial share. Asia Pacific is projected to witness the fastest growth owing to greater focus of key players to tap opportunities in emerging nations like China and India.
• New product approvals and launches by the pioneer market players will offer lucrative opportunities for market expansion. Numerous players are engaged in R&D to develop novel ECM technologies for improved healing. Partnerships with medical technology companies and academic institutes are helping them strengthen their product portfolios. More clinical research on exploring therapeutic benefits for other conditions like CVDs and neurological disorders may open up new application areas over the coming years.
• In summary, though initial costs pose a challenge, rising prevalence of target disorders represents a favorable influence on global ECM sales in the long term. Developing markets add growth prospects.

Extracellular Matrix Market Drivers

• Increasing demand for regenerative medicines: The rising demand for regenerative medicines is driving growth of the extracellular matrix market. ECM is an integral component of regenerative medicines used for repairing and regenerating damaged tissues. According to estimates, the global regenerative medicines market is projected to reach US$ 79.8 Mn by 2026 from US$ 40.3 Mn in 2021, at a CAGR of 15%. Companies such as Integra LifeSciences, a medical device company, Aziyo Biologics, a healthcare company, and CollPlant Biotechnologies, a biotechnology company, are focused on leveraging ECM for regenerative medicine applications.
• Rising prevalence of chronic diseases: The growing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular diseases is fueling demand for advanced wound healing products, including those based on ECM. According to the World Health Organization, by 2020, chronic diseases accounted for 60% of the global disease burden. ECM products such as hydrogels and scaffolds aid in faster wound recovery. Players such as Smith & Nephew, Organogenesis, and MIMETAS are offering ECM wound care products.
• Technological advancements in 3D cell culture: Advances in 3D cell culture using ECM are providing new avenues for in vitro drug testing and toxicology studies. The integration of ECM in 3D cell cultures provides cells with structural and biochemical cues akin to native environment. Companies such as AMS Biotechnology, Thermo Fisher Scientific, and Merck KGaA offer 3D cell culture ECM products. The global 3D cell culture market is projected to reach US$ 5.2 Mn by 2025 from US$ 1.8 Mn in 2019.
• Rising investments by companies: Key market players are investing significantly to expand their product portfolios to gain greater market share. For instance, in January 2022, Engitix, a healthcare company, announced that Series A funding of US$54 million had been raised. The company intends to use the funds to grow its staff, infrastructure, and operations in addition to advancing its drug discovery pipeline for cancer and fibrosis. Based on its innovative, pioneering proprietary human extracellular matrix (ECM) drug discovery platform, Engitix has created two noteworthy partnerships and a portfolio of initiatives in fibrosis and solid tumors.

Extracellular Matrix Market Opportunities

• Leveraging ECM for organ-on-chip platforms: Organ-on-chip platforms incorporating ECM offer new avenues for in vitro disease modeling, drug testing, and precision medicine applications. Companies such as Emulate, MIMETAS, AIM Biotech, and Nortis are investing in developing organ chips using ECM for applications in pharmaceutical testing and personalized therapies. The potential of ECM to enhance functionality of organ chips is expected to provide significant growth opportunities.
• Developing artificial extracellular matrix for subcutaneous injection formulation: Key market players are focusing on the development and launching new products. For instance, in October 2022, Pion Inc., a healthcare company, developed and introduced the ECM-XR, a new artificial extracellular matrix (ECM), to allow faster formulation development with less reliance on in vivo testing. The ECM-XR has the stability required to study drug release over extended periods of time. In tests with a range of drugs, including small molecules, peptides, proteins, and monoclonal antibodies, it demonstrated clinically relevant in vitro release profiles.
• Emerging Markets in Asia Pacific and Latin America: Emerging markets in Asia Pacific and Latin America offer promising opportunities for growth in the extracellular matrix market. These regions are undergoing rapid economic development, which is driving improved standards of living and healthcare access. According to data from the World Bank, average GDP growth in Asia Pacific and Latin America is projected to outpace global averages over the next few years. This steady economic growth will enable more individuals to seek high-quality medical care. Since extracellular matrices are used in wound healing and tissue regeneration, rising incomes mean more people will be able to afford advanced therapies that incorporate these products. Population dynamics also point to expanding market potential. Data from the United Nations shows that Asia Pacific and Latin America together account for over half the world's population. Both regions have large, youthful populations that will place increasing demands on their healthcare systems. Many countries are also experiencing epidemiological transitions where non-communicable diseases are becoming more prevalent alongside injuries from accidents. This raises the clinical utility of extracellular matrices, which support tissue repair.
• New Application Areas Like 3D Bioprinting: 3D bioprinting holds immense promise in the field of extracellular matrix market. It allows for the precise deposition of biomaterials such as scaffolds, growth factors, living cells and supporting components that closely mimic the native tissue extracellular matrix architecture. Some of the emerging applications of 3D bioprinting could potentially benefit the market in unprecedented ways. For example, bioprinting techniques now enable the fabrication of human organs and tissues such as skin, bones, cardiac, and nerve grafts. This can help address the severe shortage of organ donors for transplantation. Rather than whole organs, bioprinting may be first utilized to produce organ constructs or patches that can be implanted or used for drug testing and development. Several trials are also underway to generate bioprinted skin constructs for wound healing applications. Another key area is producing patient-specific grafts for regenerative therapies. By incorporating a patient's own cells, 3D bioprinting can fabricate customized tissue implants that will eliminate issues such as biomaterial rejection. This is critical in therapies for chronic diseases like arthritis, where damaged cartilage needs to be replaced. Such personally tailored medical solutions will drive greater demand for biomaterials and ECM compositions. The growing role of 3D bioprinting technologies could redefine the landscape of modern medicine and extend patient longevity in the coming years.

Extracellular Matrix Market Trends

• Increasing demand for 3D bioprinting: The rising adoption of 3D bioprinting technologies for engineering functional tissue constructs is favoring demand for tunable and printable ECM bioinks. Key players such as CollPlant Biotechnologies, RegenHU, and other maker players are developing 3D bioprintable ECM bioinks. Moreover, the development of hybrid ECM bioinks combining natural and synthetic polymers to achieve optimal printability and mechanical integrity has emerged as an important trend.
• Shift towards organ-specific ECM: The focus on developing organ-specific ECM scaffolds that highly mimic native cellular microenvironments has increased. Companies are expanding their capabilities to harvest organ-specific ECMs such as cardiac, renal, and hepatic ECM. The launch of products such as CorMatrix CanGaroo for cardiac-specific applications validates this trend. The shift towards organomimetic scaffolds with the innate complexity of tissue ECM supports market growth.
• Rising demand for reinforced ECM: Reinforcing ECM scaffolds with nanoparticles, growth factors, and other biomolecules is gaining traction for tissue engineering applications requiring greater mechanical strength and bioactivity. For instance, collagen scaffolds reinforced with iron oxide nanoparticles, nanocellulose, nanofibers, and other structures are being evaluated. Players such as Advanced BioMatrix and Matricel offer reinforced ECM products. The trend is expected to continue with increasing R&D on reinforced ECM composites.
• Combination with stem cell therapies: The utilization of ECM scaffolds as delivery vehicles for stem cell therapies is rising given their innate capacity to bind and release growth factors. Players such as Cook Medical, Integra LifeSciences, and Aziyo Biologics provide ECM products optimized for stem cell loading and growth. Moreover, hybrid scaffold designs incorporating ECM with stem cell-derived matrices are also being explored. The trend is expected to expand given the synergistic effects of ECM and stem cells for regenerative therapies. 

Extracellular Matrix Market Restraints

• High costs associated with ECM-based products: Extracellular Matrix scaffolds collected from human and animal tissues undergo extensive processing increasing their cost. Moreover, product development requires significant R&D investments. The high costs of commercial ECM products limit affordability, hindering broader adoption. Companies are focused on introducing low-cost variants; however, the restraint is expected to continue over the forecast period.
• Lack of reimbursements: The lack of reimbursement for ECM biomaterials is a key factor restricting market growth. For instance, reimbursement for ECM bladder grafts such as Cytal Wound Matrix is currently limited to Medicare patients over 65 years of age undergoing specific procedures. The limited reimbursement scenario decreases product affordability for patients. Expanding reimbursement coverage for ECM scaffolds and matrices will be critical for driving adoption across patient demographics
• Limitations associated with animal-derived ECM: Issues around immunogenicity, difficult to reproduce properties, and the risk of disease transmission associated with animal-derived ECM are key challenges restraining market growth. Moreover, sourcing inconsistencies and ethical concerns limit clinical adoption of animal ECM. Players are increasingly focused on developing human and recombinant ECM scaffolds to overcome the challenges associated with animal ECM. However, the transition is expected to be slow over the coming years.

Figure 2. Global Extracellular Matrix Market Share (%), By Component Type, 2023

To learn more about this report, request a free sample copy

Recent Developments

New product launches

• In November 2021, Sanara MedTech Inc., a medical equipment manufacturer, in collaboration with Cook Biotech Inc., a biotechnology company, announced the launch of Fortify Flowable Extracellular Matrix. Fortify Flowable Extracellular Matrix is an advanced wound care device that presents SIS ECM technology in a way that can fill irregular wound shapes and depths.
• On March 2, 2023, Convatec Inc., a medical device company, received approval from the U.S. Food and Drug Administration for its InnovaBurn placental extracellular matrix medical device to treat burns and complicated surgical wounds, including second-degree partial-thickness burns.

Acquisition and partnerships

• On February 1, 2023, Baxter, a healthcare company, and Miromatrix Medical Inc., a biotechnology company, announced a partnership to develop a therapy for patients with acute liver failure (ALF). The partners will combine Miromatrix Medical Inc. single-use bioengineered liver with Baxter’s PrisMax system, which is designed to provide individualized therapies to patients.
• June 2, 2022. Lineage Cell Therapeutics, Inc., a biotechnology company, announced that it had expanded its existing collaboration with Advanced BioMatrix, a biotechnology company. Under the expanded collaboration, Advanced BioMatrix will broaden its current focus of manufacturing and supplying R&D-grade HyStem to the research community to include the development, supply, and/or licensing of clinical/commercial GMP- (Good Manufacturing Practice) grade material for its customers. HyStem is a hydrogel that copies the extracellular matrix that surrounds cells in organs and tissues and is necessary for both tissue structure and cellular activity.

Top companies in Extracellular Matrix Market

• Thermo Fisher Scientific
• DSM 
• Acelity (KCI Concepts)
• Corning Incorporated
• Baxter
• FUJIFILM Holdings Corporation
• Integra LifeSciences
• CellSystems Biotechnologie Vertrieb GmbH
• Biotime, Inc.
• Trevigen, Inc. 
• Advanced BioMatrix
• Collagen Matrix, Inc.
• Merck KGaA
• VWR International LLC
• REPROCELL USA Inc.
• BioLamina AB
• Matricel GmbH
• Tissue Regenix
• Admedus
• MIMETAS

*Definition: Extracellular matrix (ECM) refers to the complex network of proteins, glycoproteins, proteoglycans, and polysaccharides that provide structural and biochemical support to surrounding cells in tissues. ECM plays a vital role in regulating cellular behavior, differentiation, migration, proliferation, adhesion, and signaling. ECM components interact dynamically with cells to maintain tissue homeostasis and drive repair and regeneration. Key components of ECM include collagen, elastin, fibronectin, laminins, and various growth factors. Medically, ECM derived scaffolds and hydrogels have applications in regenerative medicine for repairing damaged tissues and inducing healing in cases of chronic wounds. ECM biomaterials provide a mechanically supportive framework enriched in tissue-specific cues to drive reconstructive processes. Advanced engineered ECM constructs are being leveraged in 3D bioprinting, drug discovery, and development of organs-on-chip. Overall, ECM represents a biologically multi-functional scaffolding milieu present in native tissues that is being harnessed for therapeutic as well as in vitro modeling applications across healthcare and life science sectors.